ECSP11010867A - Compuestos novedosos de fenilamino-isonicotinamida - Google Patents

Compuestos novedosos de fenilamino-isonicotinamida

Info

Publication number
ECSP11010867A
ECSP11010867A EC2011010867A ECSP11010867A ECSP11010867A EC SP11010867 A ECSP11010867 A EC SP11010867A EC 2011010867 A EC2011010867 A EC 2011010867A EC SP11010867 A ECSP11010867 A EC SP11010867A EC SP11010867 A ECSP11010867 A EC SP11010867A
Authority
EC
Ecuador
Prior art keywords
phenylamine
new
isonicotinamide compounds
isonicotinamide
compounds
Prior art date
Application number
EC2011010867A
Other languages
English (en)
Inventor
Jr Benny C Askew
Andrea Goutopoulos
Henry Yu
Bujalski Lesley Liu
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP11010867A publication Critical patent/ECSP11010867A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona compuestos novedosos de acuerdo con la Fórmula (I)su manufactura y uso para el tratamiento de enfermedades hiperproliferativas, tales como cáncer, restenosis e inflamación.
EC2011010867A 2008-08-04 2011-03-03 Compuestos novedosos de fenilamino-isonicotinamida ECSP11010867A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13785808P 2008-08-04 2008-08-04

Publications (1)

Publication Number Publication Date
ECSP11010867A true ECSP11010867A (es) 2011-04-29

Family

ID=41078311

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010867A ECSP11010867A (es) 2008-08-04 2011-03-03 Compuestos novedosos de fenilamino-isonicotinamida

Country Status (28)

Country Link
US (2) US8404725B2 (es)
EP (1) EP2307376B1 (es)
JP (1) JP2011529963A (es)
KR (1) KR101651700B1 (es)
CN (1) CN102099336B (es)
AR (1) AR072904A1 (es)
AU (1) AU2009279940B2 (es)
BR (1) BRPI0916566B8 (es)
CA (1) CA2732828C (es)
CL (1) CL2011000258A1 (es)
CO (1) CO6341612A2 (es)
DK (1) DK2307376T3 (es)
EA (1) EA018539B1 (es)
EC (1) ECSP11010867A (es)
ES (1) ES2560878T3 (es)
HR (1) HRP20160044T1 (es)
HU (1) HUE027223T2 (es)
IL (1) IL210937A (es)
MX (1) MX2011001127A (es)
MY (1) MY151342A (es)
NZ (1) NZ591498A (es)
PE (1) PE20110665A1 (es)
PL (1) PL2307376T3 (es)
PT (1) PT2307376E (es)
SI (1) SI2307376T1 (es)
UA (1) UA107183C2 (es)
WO (1) WO2010017051A1 (es)
ZA (1) ZA201101661B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2588452A1 (en) * 2010-07-01 2013-05-08 Merck Patent GmbH Method for the preparation of cis-1,2-diols in the kilogram scale
WO2012055953A1 (en) * 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
SI2760821T1 (en) 2011-09-02 2018-02-28 Novartis Ag A salt salt of an anti-inflammatory substituted cyclobutenedione compound
CA2920376A1 (en) 2013-08-07 2015-02-12 Martin Blomberg JENSEN Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
NZ730728A (en) 2014-11-20 2022-04-29 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
CN106632021A (zh) * 2016-09-27 2017-05-10 中国药科大学 2‑取代异烟酸类化合物、其制备方法及其用途
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
NZ501277A (en) 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
IL132840A (en) 1997-07-01 2004-12-15 Warner Lambert Co Derivatives 4 - bromo or 4 - benzohydroxamic acid iodine amino iodine and pharmaceutical preparations containing them for use as MEK inhibitors
WO2000041505A2 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Anthranilic acid derivatives
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
JP2002534497A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー スルホヒドロキサム酸およびスルホヒドロキサメートおよびｍｅｋ阻害剤としてのその使用
HRP20010524A2 (en) 1999-01-13 2002-08-31 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
AU2201500A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
AU2482700A (en) 1999-01-13 2000-08-01 Warner-Lambert Company 1-heterocycle substituted diarylamines
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CA2403017A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
CA2416685C (en) 2000-07-19 2008-10-07 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
RU2300528C2 (ru) 2002-03-13 2007-06-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
MX2007004781A (es) * 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
US7897624B2 (en) 2006-04-18 2011-03-01 Ardea Biosciences Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
JP5311673B2 (ja) 2006-12-14 2013-10-09 エグゼリクシス， インコーポレイテッド Ｍｅｋ阻害剤の使用方法

Also Published As

Publication number Publication date
EA018539B1 (ru) 2013-08-30
EP2307376A1 (en) 2011-04-13
SI2307376T1 (sl) 2016-02-29
CA2732828C (en) 2017-06-13
EA201100296A1 (ru) 2011-08-30
WO2010017051A1 (en) 2010-02-11
US8404725B2 (en) 2013-03-26
ES2560878T3 (es) 2016-02-23
IL210937A0 (en) 2011-04-28
EP2307376B1 (en) 2015-11-04
AR072904A1 (es) 2010-09-29
US20130184314A1 (en) 2013-07-18
MX2011001127A (es) 2011-03-21
CL2011000258A1 (es) 2011-07-29
PE20110665A1 (es) 2011-09-23
HUE027223T2 (en) 2016-08-29
NZ591498A (en) 2012-09-28
DK2307376T3 (en) 2016-01-11
HK1159097A1 (en) 2012-07-27
CN102099336A (zh) 2011-06-15
CA2732828A1 (en) 2010-02-11
BRPI0916566B8 (pt) 2021-05-25
BRPI0916566B1 (pt) 2020-03-10
PL2307376T3 (pl) 2016-04-29
IL210937A (en) 2015-07-30
KR101651700B1 (ko) 2016-08-26
CN102099336B (zh) 2013-11-06
MY151342A (en) 2014-05-15
PT2307376E (pt) 2016-02-26
US8889719B2 (en) 2014-11-18
JP2011529963A (ja) 2011-12-15
KR20110044768A (ko) 2011-04-29
AU2009279940B2 (en) 2014-01-16
UA107183C2 (uk) 2014-12-10
ZA201101661B (en) 2011-11-30
CO6341612A2 (es) 2011-11-21
US20110184032A1 (en) 2011-07-28
AU2009279940A1 (en) 2010-02-11
HRP20160044T1 (hr) 2016-02-26
BRPI0916566A2 (pt) 2015-11-10

Similar Documents

Publication Publication Date Title
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida
CO6721019A2 (es) Quinazolincarboxamida azetidinas
CO6511283A2 (es) Primidinas sustituidas útiles en el tratamiento de enfermedades tales como cancer
DOP2010000270A (es) Derivados de azetidina y ciclobutano como inhibidores de jak
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CR8919A (es) Analogos de tetrapeptidos
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
NI201200023A (es) Derivados de 5-fluoropirimidinona
EA201170521A1 (ru) Новые соединения
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
MX2012012527A (es) Compuestos quimicos.
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
CU20120101A7 (es) Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
CO6470845A2 (es) Derivados de pirimidina novedosos y su uso en el tratamiento del cancer y enfermedades adicionales
UY33199A (es) 5-alquinil-pirimidinas.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
UY32918A (es) Nuevos compuestos de 2-piridona
EA201400339A1 (ru) Новые имидазоламины в качестве модуляторов киназной активности
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CU20090009A7 (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
ECSP11010816A (es) Nuevos Compuestos